MariMed Q1 2026 Earnings Report

MariMed EPS Results

• Actual EPS: -$0.01
• Consensus EPS: -$0.01
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

MariMed Revenue Results

• Actual Revenue: $39.48 million
• Expected Revenue: $38.75 million
• Beat/Miss: Beat by +$731.00 thousand
• YoY Revenue Growth: N/A

MariMed Announcement Details

• Quarter: Q1 2026
• Date: 5/13/2026
• Time: After Market Closes
• Conference Call Date: Thursday, May 14, 2026
• Conference Call Time: 8:00AM ET

MariMed (OTCMKTS:MRMD), Inc. is a U.S. cannabis company that develops, operates and manages regulated cannabis cultivation, processing and retail facilities. The company follows a vertically integrated business model, producing cannabis products and selling them through its own dispensaries and other authorized channels.

MariMed offers a range of cannabis products, including flower, pre-rolls, concentrates, edibles, tinctures and topical products. Its portfolio includes brands such as Betty’s Eddies, Nature’s Heritage, Bubby’s Baked and Kalm Fusion, which are marketed for recreational and medical-use consumers where permitted by state law.

The company serves regulated cannabis markets in several states, including Delaware, Maryland, Massachusetts and Ohio. MariMed was established in 2011 and is headquartered in Newton, Massachusetts. Jon Levine, a co-founder of the company, serves as its chief executive officer.

MariMed Q1 2026 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: MariMed reported Q1 2026 revenue of $39.5 million, adjusted EBITDA of $3.6 million, and positive cash flow from operations, showing continued profitability and cash generation despite a challenging market.
• Positive Sentiment: Wholesale momentum remained strong, with Illinois wholesale revenue up 25% quarter over quarter and Delaware up 13%. Management said its brands continue to hold leading positions across core markets, including Betty’s Eddies as the top-selling edible across multiple states.
• Neutral Sentiment: Retail revenue grew 5% year over year and was supported by Delaware’s adult-use expansion, growth at the Upper Marlboro store, and a loyalty program that now drives about 80% of retail revenue. The company also said it has about 398,000 active loyalty members and more than half of orders are placed online before store visits.
• Positive Sentiment: Management highlighted several growth avenues, including new store expansion in Ohio, a planned processing kitchen in New York, and ongoing licensing opportunities in Pennsylvania and Maine. It also pointed to Massachusetts’ expanded dispensary cap as a potential opportunity for additional retail M&A.
• Positive Sentiment: The company expects the rescheduling of medical cannabis to provide an immediate tax benefit by eliminating 280E-related taxes on the medical portion of the business. Management said this should improve cash flow, while noting broader benefits will depend on further federal guidance and possible future reform.

Presentation

[Operator]

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the MariMed Inc. First Quarter 2026 financial results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. To ask a question, simply press star one on your telephone keypad. To withdraw your question, press star one again. It is now my pleasure to turn the call over to Alex Swartz, Regional Store Director for MariMed. You may begin.

[Alex Swartz, Regional Retail Director at MariMed]

Hello, good morning, everyone. I'm Alex Swartz, Regional Retail Director for MariMed in Maryland and Delaware. I'm honored to kick off today's 2026 First Quarter Earnings Call. I'm privileged to work with amazing teams in those states to deliver our high standard of exceptional service to our customers every day. Through constant collaboration with my retail teammates in MariMed's other regions, I know that every Thrive employee across 13 dispensaries is dedicated to doing the same thing. We have a unified brand, but more importantly, we have a unified mission, and it's a huge part of what I believe makes Thrive the dispensary of choice for so many people. Joining the call today are Jon Levine, our Chief Executive Officer, Ryan Crandall, our Chief Commercial Officer, and Mario Pinho, our Chief Financial Officer. This call will be archived on our investor relations website and contains forward-looking statements.

[Alex Swartz, Regional Retail Director at MariMed]

Actual events or results may differ materially from these forward-looking statements and are subject to various risks and uncertainties. These risks are discussed in the Risk Factors sections of our 10-K and 10-Q available on our website. Any forward-looking statements reflect management's expectations as of today, and we assume no obligation to update them unless required by law. Additionally, we refer to certain non-GAAP financial measures, which are reconciled in our earnings release. I will now turn the call over to Jon for his opening.

[Jon Levine, CEO at MariMed]

Thank you, Alex. Good morning, everyone. Last night, we reported first quarter 2026 revenue of $39.5 million and positive adjusted EBITDA of $3.6 million. Additionally, we once again generated positive cash flow from operations. That performance was the result of our operational discipline and the strength of our brands and was achieved despite the adverse market dynamics that persist across our industry. Of particular note was our wholesale performance in Illinois and Delaware, where our cultivation, manufacturing, distribution, and marketing teams delivered outstanding results. We grew quarter-over-quarter wholesale revenue in Illinois by 25% and in Delaware by 13%, widening our leadership position in Delaware, where we are already the number one wholesaler. In fact, our products maintain market-leading positions across all of our core markets. Betty's Eddies was once again the number one-selling edible across Illinois, Massachusetts, Maryland, and Delaware combined.

[Jon Levine, CEO at MariMed]

Our Vibations powdered drink mix maintained a top five share across the same states. Ryan is going to provide a deeper dive into our first quarter results in each of our markets. I'll now turn to the status of our primary growth drivers I have outlined during our March earnings call. In Pennsylvania, our licensing partner is awaiting state approval of our products and packaging. We remain confident about the revenue potential of our brands in Pennsylvania, especially with adult use sales likely to commence in the near future, as well as our success to date in neighboring states of Maryland and Delaware. In New York, we remain on schedule with our plan there. Construction has begun on the processing kitchen we are building with our licensed partner in the Bronx.

[Jon Levine, CEO at MariMed]

We're forecasting licensing revenue generation in both states early next year while doing everything in our control to help speed up this timeline. In Maine, where we also maintain a licensing agreement, distribution of Betty's Eddies continues to expand. Our commercial partner began sales during the fourth quarter of 2025 and has continued to sell into new dispensaries through the first quarter. Licensing allows us to generate revenue and expand our distribution in capital-efficient manner. We will continue to pursue additional agreements in tandem with M&A, which remains a focused avenue of growth for MariMed. To that point, we are excited about recent developments in Massachusetts, where the dispensary limit cap has increased from three to six. We're very interested in pursuing opportunities to add additional stores in our home state.

[Jon Levine, CEO at MariMed]

Our dispensary footprint will expand in Ohio first. Where we're leveraging our second retail license there to open a new Thrive location in the Columbus area. We anticipate that store will open before the end of the year. We also look forward to the benefits that the recent rescheduling of medical cannabis will have on MariMed and the nation. Near term, it locks in the elimination of 280E related taxes for medical portion of our business. There are still many questions to be answered about the rescheduling. Make no mistake, this is the single biggest piece of federal drug reform in our country's history, and we're thankful for the administration for getting it done. For me, it's particularly personal moment. Bob Fireman and I founded MariMed more than a decade ago as a medical cannabis company born out of a passion, belief in the plant's medicinal value.

[Jon Levine, CEO at MariMed]

In fact, our name MariMed was created as shorthand for marijuana medicine. I am beyond grateful that the federal government has finally acknowledged what we've always known about the plant's medicinal value. That said, this is only step one. We are hopeful that the rescheduling of recreational cannabis will soon follow. In the meantime, we are in the process of registering with the DEA, and we will keep our eyes on the Treasurer's guidance with respect to the details about the implementation of 280E tax relief. To our investors, thank you for your continued support. Our equity remains significantly undervalued, given the strength of our balance sheet. The fact that we own our real estate and the value of our brands, we are confident it is only a matter of time before the markets appreciate what we have created at MariMed and the bright future ahead of us.

[Jon Levine, CEO at MariMed]

I'll now turn the call over to Ryan.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Thanks, Jon, and good morning, everyone. Let me walk you through our revenue performance at a high level and then across each of our core markets. Our sales, marketing, and operations teams delivered another strong quarter, with wholesale revenue increasing 4% year-over-year and declining 1% sequentially. Several factors drove our year-over-year wholesale performance. First, we maintained deep penetration with coverage in 84% of available storefronts across our core markets on a trailing-year basis. Second, were the contributions of our Illinois and Delaware teams, which I'll review in my state-to-state rundown. The sequential decline was expected and consistent with seasonal trends the industry experiences each year from Q4 to Q1. Turning to retail, we achieved year-over-year growth of 5% during the first quarter and a 7% decline sequentially.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Primary contributors to the year-on-year growth were Delaware's adult use expansion that occurred mid-year, significant growth that we achieved at our Upper Marlboro store in Maryland, and continued growth of our loyalty program, which accounted for approximately 80% of our overall retail revenue. We grew our membership count by 10% during the first quarter of 2026. That's significant because the average basket of our members was 2% higher than non-members during the quarter, an improvement of 100 basis points versus last quarter. We believe it's directly attributable to the personalized offerings we're now delivering through the new Thrive app we launched during the quarter. Turning to our individual markets. In Delaware, wholesale sales continued to grow since the commencement of adult use sales in August of last year, increasing 13% sequentially and 373% year-over-year on a pro forma basis.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Our brand portfolio again achieved the number one overall market share position in the quarter, with Betty's, Bubby's, and Vibations all owning the top spot in their respective categories. The combination of Nature's Heritage and First State branded flower captured the number one spot in the flower category. At retail, revenue declined 12% sequentially and increased 24% year-on-year on a pro forma basis. The sequential decline was in line with our expectations, given the seasonality of that market. In Massachusetts, wholesale revenue increased 1% year-on-year and decreased 4% sequentially. According to Hoodie, we outperforming the industry in the state both year-over-year and sequentially on the strength of our brands. Betty's Eddies and Bubby's Baked maintain the number one sales position in their respective edible categories, and Nature's Heritage concentrates captured the number one position, up from number four at the end of Q4.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Vibations, Nature's Heritage pre-rolls, and InHouse gummies all once again ranked in the top 10 in their respective categories. Our retail revenue declined 9% year-on-year and 10% sequentially in Massachusetts, where average order volume decreased approximately $2 per basket during the quarter. We will continue to double down and refine our loyalty program, our new Thrive app, and our digital and in-store customer experiences to drive new customer engagement and existing customer retention. In Maryland, wholesale sales declined 12% year-on-year and 8% sequentially. The result of isolated production issues that we have already resolved and are recovering from this quarter.

[Ryan Crandall, Chief Commercial Officer at MariMed]

The resolve of our brands shined through during the quarter with Betty's Eddies, Bubby's Baked, Vibations, and InHouse gummies all ranking in the top three in their respective categories by market share. Retail revenue in Maryland declined 5% year-over-year, but increased 24% sequentially, with our Upper Marlboro store continuing to outperform expectations. Turning to Illinois, where we began distributing our brands in a crowded market just a few years ago, wholesale revenue increased 22% year-on-year and increased 25% sequentially. Our standout performers were once again Betty's Eddies, which was the 13th best-selling edible in the state during the first quarter, and Vibations, which maintained its number six ranking among beverages.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Notably, Nature's Heritage flower, which didn't launch in Illinois until late 2024, cracked the top 50 flower brands in the state for the first time, moving up 15 places from 61 to 46. Retail sales in Illinois declined 10% year-on-year and 2% sequentially, principally due to AOV pressure. In summary, I'm pleased to see our brands continue to capture a meaningful share where they're available. While competitive brands come and go, our core products have stood the test of time for more than a decade. Quarter-after-quarter and year-after-year, regardless of changes in the competitive landscape or market dynamics like price compression, Betty's, Nature's, and our other brands have shown the resilience, the consumer trust, and the staying power that the world's most beloved CPG brands must have to defend their turf. We are not standing pat.

[Ryan Crandall, Chief Commercial Officer at MariMed]

We are continuing to lean in on our product innovation to grab more market share. To that point, we've got a number of new line extensions and limited time special SKUs scheduled to roll out soon that will continue to gain new customers and create deeper loyalty with our existing base. Before handing the call over to Mario for his financial review, I wanna thank our teams for executing well within a challenging environment.

[Mario Pinho, CFO at MariMed]

Thank you, Ryan, and good morning, everyone. Turning to our financial results for the first quarter. Revenue for Q1 was $39.5 million, reflecting expected seasonal softness sequentially, while continuing to grow year-over-year. On a sequential basis, revenue declined $2.2 million or 5.2% compared to Q4. This decline was primarily driven by lower retail volume, which was expected due to seasonality. AOV remains stable and across our markets, we continue to see healthy unit demand, particularly in wholesale, where increased distribution and brand penetration are driving volume growth. Within wholesale, lower realized pricing in Delaware was partially offset by stronger unit volumes, particularly in that state as well as in Illinois. On a year-over-year basis, revenue increased $1.6 million or 4.2%, driven by continued retail expansion, including adult use in Delaware and increased penetration in wholesale distribution.

[Mario Pinho, CFO at MariMed]

These gains more than offset lower pricing in our more mature markets. Overall, our revenue performance reflects continued underlying demand for our brands, stable market share, and the strength of our wholesale platform. Importantly, this demonstrates the resilience of our model with volume growth and distribution gains helping to offset a more competitive pricing environment. Gross profit was $15.8 million with a gross margin of 40.1%. On a sequential basis, gross margin was relatively stable, increasing approximately 20 basis points. This reflects continued operational discipline with retail performance and contributions from our Delaware operations, largely offsetting expected mix shifts towards wholesale. On a year-over-year basis, gross margin declined approximately 110 basis points, reflecting mix shifts towards wholesale, partially offset by retail margin improvement and operational efficiencies.

[Mario Pinho, CFO at MariMed]

Overall, we continue to maintain margins at or above 40%, supported by strong brand positioning, disciplined cost management, and efficiencies across our vertically integrated platform. Operating expenses were $14.4 million on a sequential basis. Operating expenses decreased slightly by approximately $100,000. On a year-over-year basis, operating expenses declined by approximately $500,000, driven by lower bad debt expense and reduced marketing spend, partially offset by investments in infrastructure, including IT and finance capabilities. Operating income was $1.4 million in Q1 compared to $2.4 million in Q4, reflecting the impact of lower revenue and margin pressure sequentially. On a year-over-year basis, operating income improved significantly from $700,000, demonstrating improved scale and cost discipline. Adjusted EBITDA was $3.6 million, representing an EBITDA margin of 9%.

[Mario Pinho, CFO at MariMed]

On a sequential basis, EBITDA declined by approximately $800,000, primarily driven by lower revenue and mix, along with modest increases in personnel-related expenses. On a year-over-year basis, EBITDA increased by approximately $1.1 million, with margin expanding from 7% to 9%, reflecting revenue growth, improved operating leverage and lower bad debt expense. Taken together, these results highlight improving operating leverage in the business. As we scale revenue, we are maintaining cost discipline, which is translating into stronger year-over-year profitability. GAAP net loss for the quarter was $3.8 million compared to a net loss of $4.6 million in Q4, driven primarily by an accounting gain we recognized on the refinancing of our legacy Series B preferred stock and by improved operating performance.

[Mario Pinho, CFO at MariMed]

On a year-over-year basis, GAAP net income improved significantly from a loss of $5.4 million in the first quarter of 2025, reflecting both stronger operating results in 2026 and a non-recurring bad debt accounting write-off taken in 2025. Turning to our balance sheet and liquidity. We ended the quarter with $7.9 million in cash and cash equivalents, down $1 million from $8.9 million at the end of 2025. We generated positive operating cash flow in the quarter while investing modestly at approximately $800,000, primarily related to targeting capital expenditures and license renewals. From a capital and finance perspective, after restructuring the Series B preferred shares with Navy Capital, our current liquidity position will provide sufficient flexibility to support operations and execute on our near-term growth initiatives.

[Mario Pinho, CFO at MariMed]

Overall, Q1 results reflect continued year-over-year growth supported by retail expansion and wholesale distribution gains. Stable gross margins demonstrating the strength of our model despite a more competitive pricing environment and targeted capital allocation to fuel our growth. As Jon mentioned, we are thrilled with the rescheduling news announced on April 22nd. Approximately 20% of our first quarter retail revenue were medical sales. Therefore, this change should drive an immediate benefit from a tax perspective. Pending further movements in Washington and further guidance on implementation, including timing and any transitional considerations, we will continue to monitor developments, including the outcome of the planned mid-year hearings. In the meantime, we remain focused on execution and believe MariMed is well-positioned to benefit as clarity emerges. I'll now turn it over to Jon for closing remarks.

[Jon Levine, CEO at MariMed]

Thank you, Mario. Before we take questions, I wanna thank our employees. They are what fuels my optimism about our future every day. Their tireless efforts and contributions are the backbone of our success. Operator, you can now open the line for questions.

[Operator]

As a reminder, to ask a question, simply press star one on your telephone keypad. Again, that is star one to ask a question. Our first question comes from the line of Pablo Zuanic with Zuanic & Associates. Please go ahead.

[Pablo Zuanic, Analyst at Zuanic & Associates]

Thank you. Good morning, everyone. Jon, can you expand on how rescheduling, as it's been announced, how does that change your strategy? Does it make you, I know that M&A is part of a growth strategy, but does this make you more acquisitive or more intent on growing through M&A? If you can give nuance there in terms of growing in an asset-light way versus in terms of licensing versus actually buying businesses and hard assets in other states. Thanks. Let's start with that.

[Jon Levine, CEO at MariMed]

Morning, Pablo. Thank you for the question, and thank you for joining the call. Yes, you know, there's a few factors that have made us change a little bit our thoughts because not just the rescheduling but also Massachusetts changing their limits here in the state. We're looking at expanding more retail in Massachusetts now that we're able to, which will help us get the additional margins. That will also give us the ability to also look at additional medical facilities here in Massachusetts so that we can get to our maximum of six apiece.

[Jon Levine, CEO at MariMed]

We're gonna look at expansion in other states the way that we still have been to add additional retail and some licensing or purchasing of other licenses in states where we can go in with, the process to expand our brand and get the brands into as many states as possible. We're very excited about the opportunity in New York and Pennsylvania to bring our brands into those states. I think that the rescheduling and the adult use in the future in Pennsylvania will be positive impact on us.

[Pablo Zuanic, Analyst at Zuanic & Associates]

Thank you for that. Just if you can expand on the theme of gaining depth versus, you know, entering new states. By that I mean, for example, in those licensing states, could you actually be in a position to buy the assets, to buy those businesses? Is it more about entering other states? Just trying to understand the M&A part from a gaining depth component versus actually entering new states.

[Jon Levine, CEO at MariMed]

With expanding the brands, you know, manufacturing, the rescheduling isn't as big of an effect. The retail would be the concentration of expanding into additional states, especially ones with medical at first because of the fact that the medical has had the conversion to a reschedule and the adult use is still under review. It's a matter of looking at the license of our products. We're still on the same schedule of looking at whether it's a partnership or if it makes more sense to go out and use our cash flow or raising money to buy additional state licenses for processing. It still hasn't changed much because the 280E.

[Jon Levine, CEO at MariMed]

On the retail side, the fact that people won't be able to get the credits to have the cash flow if it's adult only. This is a medical-only change right now, and we're hopeful to see the adult use change in the near future.

[Pablo Zuanic, Analyst at Zuanic & Associates]

Thank you. Maybe for Ryan, I guess a two-part question. You know, other companies are talking about more price stabilization in some markets, not necessarily everywhere. If you can, you know, discuss that in your top four in your top markets, what are you seeing in terms of pricing and are things beginning to stabilize? If you can touch on that. Let's start with that, Ryan, first. Thanks.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Sure, Pablo. Thank you for the question. In terms of price stabilization, I think you really gotta look at it by category. I think there are still categories that are stressed by price compression, you know, in several of these markets. I feel like, you know, when we look at Illinois, we still see prices, you know, more aggressively pricing, and I think there's more producers coming online. As we look at that, I think Illinois still has a way to go. Massachusetts appears at times to have stabilized and start to recover a little bit, but, you know, at the end of the day, I think it's still a dog fight in Massachusetts.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Maryland is still a difficult wholesale market, with some of the large producers there, driving price down. On the flower side, I think there is still a rock fight going on out there in many markets. I think the edibles have been, you know, for a large part protected. You look, some of the newer innovation products around infused pre-rolls and some of those categories, rosin, you know, tend to get a premium and tend to be a little bit more stable from a price standpoint. You know, traditional vapes, you know, traditional pre-rolls, you know, jarred flower, you know, larger format flower, there's still a lot of price compression in these markets.

[Ryan Crandall, Chief Commercial Officer at MariMed]

I think Delaware, probably has the least amount of compression at this point, but that will be at some point in the future.

[Pablo Zuanic, Analyst at Zuanic & Associates]

Right. Thank you. Staying with Ryan, in terms of retail, I mean, we track what we call revenue per store by state very closely, right? In some states, little total sales growth, but there's more stores, so it means that there's revenue per store erosion. I understand, I guess, from Maryland, there's a pretty much a cap on total stores, right? Can you just differentiate in terms of how bad has it gotten in terms of revenue per store erosion comparing, say, Illinois versus Massachusetts and I guess versus Maryland, although I guess in Maryland, there is a cap. Thanks.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Sure, Pablo. I appreciate the question. I think it depends on, you know, the scope of time that you look at. I think there's been erosion everywhere. I mean, I think eighths of cannabis used to be $60 an eighth, you know, $70, $65 an eighth in every market. We've seen, you know, that consistent decline, you know, of both product cost as well as overall basket across markets. I think the real, you know, The metrics that we're focused on are increasing our transactions, making sure that we increase our loyalty program, that when folks enter our store, they order it, they're getting our products, that they are returning to buy them again, and that we're making sure that we're there, that we're staying in touch with our customers and listening to them.

[Ryan Crandall, Chief Commercial Officer at MariMed]

I think that's what we're really laser focused on. Ultimately, yeah, it's a challenging environment. And same store sales have been impacted in a lot of places. I think at the end of the day, you know, the well-run businesses, you know, that continue to innovate and continue to not accept, you know, mediocre results are gonna be the ones that succeed in this environment.

[Pablo Zuanic, Analyst at Zuanic & Associates]

Right. One last one maybe for Mario. In terms of, you know, the percent of your own brands being sold in your own stores, is that where you want it to be, or is there room to increase that? If you can be specific about certain states, meaning, you know, in terms of your own Thrive stores, how much is own brands versus third party brands? Thank you.

[Mario Pinho, CFO at MariMed]

Ryan can speak a little bit more to it as well, but that is a significant and a core strategy from a sales perspective. We obviously want to increase the mix of our own products in our stores, and it's something we even have a dedicated person to that and focusing that across all markets. That is a permanent strategy that we have working, you know, in our business.

[Pablo Zuanic, Analyst at Zuanic & Associates]

Okay. Look, if, apologies if I went through.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Yeah, I can add on to that, Pablo.

[Pablo Zuanic, Analyst at Zuanic & Associates]

Go on.

[Ryan Crandall, Chief Commercial Officer at MariMed]

I can add on to that, Pablo, if you'd like. Yeah, I mean, we are very focused on making sure that our products show up in our stores, you know, better than they show up in any store. We, you know, That's first and foremost. Then second is, you know, we are focused on making sure that, you know, we're recommending our products first, and that we're giving our products every ability to sell, you know, at an increased rate over time within our stores. That is a core area of focus, and there is a team, you know, gold on successful results there.

[Pablo Zuanic, Analyst at Zuanic & Associates]

Right. Thank you. I have just one last one, and apologies to the other people on the Q&A queue here. I mean, Jon or Mario, with all the news flow on rescheduling, are you getting more inbounds in terms of M&A, meaning, you know, more bankers reaching out or more brokers reaching out or even more companies reaching out in terms of the supply of businesses available for purchase? Have those inbounds changed since the rescheduling news or not really much?

[Jon Levine, CEO at MariMed]

Thank you, Pablo. No, the inbounds of the rescheduling has not affected the M&A coming in. There has been no change in any banking because this is not affecting the banks. Banks, credit card companies, they're all acting the same as if it's still an illegal situation. This has only been approved for rescheduling of the medical, so there isn't the wide-open change across the industry. I do think you will see it as the adult use becomes rescheduled and if they pass a banking rule. There's more to come, but right now it's more about people are seeing more deals coming in Massachusetts with the change of the licensing aspect in Massachusetts more than the reschedule.

[Pablo Zuanic, Analyst at Zuanic & Associates]

All right. Thank you. That's all for me. Thank you.

[Operator]

Your next question comes from a line of Joe Gomes with NOBLE Capital Markets. Please go ahead.

[Joe Gomes, Analyst at NOBLE Capital Markets]

Good morning. Congrats on the quarter.

[Jon Levine, CEO at MariMed]

Thank you.

[Joe Gomes, Analyst at NOBLE Capital Markets]

I'd like to start out on Massachusetts, you know, with the increase from three to six. Any geographies in Massachusetts where you would prefer to look at or, you know, still more just Boston area focused? Maybe you could touch on that first.

[Jon Levine, CEO at MariMed]

Yeah. Massachusetts is an exciting opportunity, but we're not gonna rush into just trying to buy a license. We have to find one that fits into a good market, that the competition around it is gonna be something that we feel is the right competition. There's a lot of stores that are for sale in the western part of the state along the New York border that are one of maybe 50 in an area in a small little 20-mile radius, and we don't wanna go into a situation where there's an overabundance of store. We wanna find markets that will be maybe on the borders of other states, but also have the competition levels that are more reasonable, like the existing stores that we have today.

[Joe Gomes, Analyst at NOBLE Capital Markets]

Okay. Then you mentioned, pardon me, an isolated production issue in Maryland that, maybe you could give us a little more color as what happened there and are we all fixed and back to normal?

[Ryan Crandall, Chief Commercial Officer at MariMed]

Yeah Joe, thank you for the question. I mean, we did have some turnover issues for some core, some key people there that we have since recovered from. Yes, that has all been resolved, and I think we are in a great position.

[Joe Gomes, Analyst at NOBLE Capital Markets]

Okay. If I may, just, you know, on the loyalty program, you know, impressive, you know, quarter-over-quarter increases, how many people are on the loyalty program now? I think you mentioned like 80% of sales are now coming from members in the loyalty program. What percent of revenues are also coming from online sales?

[Ryan Crandall, Chief Commercial Officer at MariMed]

Sure, Joe. Thank you for the question. I can circle back with you with an exact number of the loyalty membership, but it's in the hundreds of thousands at this point of active members. You know, in terms of online sales, you know, people that put in an order before they get to the store is north of 50% at this point. As I mentioned, we just launched our new Thrive app, and that app, you know, it links loyalty well, and it really drives loyalty as a part of signing up for the app. That's been a very impactful thing to driving, you know, both increased app adoption as well as increased loyalty adoption.

[Joe Gomes, Analyst at NOBLE Capital Markets]

Okay. One more from me, if I may. The Metropolis dispensary, I know that one has been, has had some challenge, competitive challenges. I don't know if you can give us an update on how that is going these days.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Sure, Joe. Yeah. I mean, Metropolis is a fantastic store for us. Very profitable store. We're, you know, we've got two stores that opened within a mile of us, about, you know, 1.5 miles of us. You know, that impact has been felt. You know, we compete very well with those stores and, you know, ultimately, I feel like the Metropolis store has stabilized and has started to show signs of growth again.

[Joe Gomes, Analyst at NOBLE Capital Markets]

Great. Thanks. I'll get back in queue.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Joe, just to circle back on the loyalty number.

[Joe Gomes, Analyst at NOBLE Capital Markets]

Sorry. Go ahead.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Sorry.

[Jon Levine, CEO at MariMed]

You can answer. It's okay.

[Ryan Crandall, Chief Commercial Officer at MariMed]

Yeah, Joe, just to circle back on the loyalty number, it's just short of 400,000. It's 398,000 active members.

[Joe Gomes, Analyst at NOBLE Capital Markets]

Thank you.

[Operator]

Again, to ask a question, simply press star one on your telephone keypad. And with no further questions in queue, this does conclude our today's conference call. You may now disconnect.

Participants

Executives

• Alex Swartz, Regional Retail Director
• Jon Levine, CEO
• Mario Pinho, CFO
• Ryan Crandall, Chief Commercial Officer

Analysts

• Joe Gomes, Analyst at NOBLE Capital Markets
• Pablo Zuanic, Analyst at Zuanic & Associates